myasthenia gravis

Go or no go? Argenx's December showdown
EP Vantage
Wed, 12/1/21 - 10:10 am
FDA
Argenx
efgartigimod
myasthenia gravis
Calliditas
Nefcon
Merck
Keytruda
AstraZeneca's newly acquired Soliris is overpriced in myasthenia gravis, cost watchdog says
Fierce Pharma
Sun, 07/25/21 - 11:44 am
AstraZeneca
Soliris
Alexion
drug pricing
myasthenia gravis
Alexion touts new PhIII data of Soliris successor as planned AstraZeneca takeover looms
Endpoints
Fri, 07/16/21 - 10:40 am
Alexion
AstraZeneca
M&A
clinical trials
Ultomiris
myasthenia gravis
Immunovant flashes the data that made Roivant want to reacquire it at a potentially hefty premium
Endpoints
Tue, 06/1/21 - 10:53 pm
Immunovant
Roivant
myasthenia gravis
thyroid eye disease
Following the pack, Immunovant rushes into pivotal studies
EP Vantage
Wed, 08/26/20 - 11:00 am
Immunovant
clinical trials
myasthenia gravis
IMVT-1401
J&J inks $6.5B Momenta buyout to bag autoimmune drug
Fierce Biotech
Wed, 08/19/20 - 11:06 am
JNJ
Momenta Pharmaceuticals
M&A
myasthenia gravis
Biotech Argenx's autoimmune phase 3 hits goals, teeing up FDA filing
Fierce Biotech
Tue, 05/26/20 - 11:07 am
Argenx
efgartigimod
myasthenia gravis
New Research Could Help Personalize Treatment for Myasthenia Gravis
BioSpace
Sat, 08/31/19 - 07:54 pm
myasthenia gravis
Ra Pharma files $100M round as Soliris rival clears phase 2 trial
Fierce Biotech
Tue, 12/11/18 - 11:49 am
Ra Pharma
Soliris
clinical trials
myasthenia gravis
zilucoplan
BrainStorm Cell Therapeutics says stem cells helped patient with ALS and MG
Reuters
Mon, 01/6/14 - 09:55 am
ALS
BrainStorm Cell Therapeutics
stem cells
myasthenia gravis

Pages